Literature DB >> 16715351

Decline in HCV testing and compliance with guidelines in patients of Sentinelles general practitioners, 1996-2002.

Véronique Massari1, Cécile Viboud, Yves Dorléans, Antoine Flahault.   

Abstract

Between 1996 and 2002, the French Sentinelles Network observed a more than 2-fold decline in the annual rate of hepatitis C virus (HCV) screening tests prescribed by general practitioners. During this period it droped from 1080 to 450 per 100,000 inhabitants. The proportion of HCV-positives increased from 9.7% to 12.9% between 1996 and 1998 but declined steadily afterwards, reaching 7% in 2002. The majority of HCV-positive patients were men (57%), 38% were aged 30-39 years and 45% were injecting drug users. Two French guidelines for HCV screening were issued in 1997 and 2001. Of the 3462 patients with a known HCV test result, 27.4% were offered following the 1997 guidelines, among which 23.7% were HCV-positive. Of the same 3462 patients, 36.8% were offered following the extended definition of the risk group in the 2001 guidelines, among which 19.9% were positive. The percentage of subjects tested with no biological sign or clinical symptom and no HCV risk factor varies from 11% to 26% showing that SGPs carry out a targeted screening even if they deviate from the strict recommendations. Of the HCV-positive patients, 14% did not meet any criteria of the guidelines suggesting a lack of sensitivity in the current definition of patients recommended for testing.

Entities:  

Mesh:

Year:  2006        PMID: 16715351     DOI: 10.1007/s10654-006-9011-3

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  22 in total

1.  Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000.

Authors:  Josiane Pillonel; Syria Laperche; Christine Saura; Jean-Claude Desenclos; Anne-Marie Couroucé
Journal:  Transfusion       Date:  2002-08       Impact factor: 3.157

2.  Sentiweb: French communicable disease surveillance on the World Wide Web.

Authors:  E Boussard; A Flahault; J F Vibert; A J Valleron
Journal:  BMJ       Date:  1996-11-30

3.  How do general practitioners approach hepatitis C virus screening in France?

Authors:  V Massari; O Retel; A Flahault
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

4.  The impact of diagnosis of hepatitis C virus on quality of life.

Authors:  A J Rodger; D Jolley; S C Thompson; A Lanigan; N Crofts
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

5.  Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe.

Authors:  S Deuffic; T Poynard; A J Valleron
Journal:  J Viral Hepat       Date:  1999-09       Impact factor: 3.728

6.  Hepatitis C in France: a national survey in the Departments of Internal Medicine and Infectious Diseases. The GERMIVIC (Joint Study Group on Hepatitis C virus of the French National Society of Internal Medicine and the French Society of Infectious Diseases).

Authors:  G Raguin; E Rosenthal; P Cacoub; P Veyssier; J C Piette; M Micoud
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

7.  Suicide and attempted suicide in France: results of a general practice sentinel network, 1999-2001.

Authors:  Françoise Le Pont; Laurent Letrilliart; Véronique Massari; Yves Dorléans; Guy Thomas; Antoine Flahault
Journal:  Br J Gen Pract       Date:  2004-04       Impact factor: 5.386

8.  Risk factors of influenza transmission in households.

Authors:  Cécile Viboud; Pierre-Yves Boëlle; Simon Cauchemez; Audrey Lavenu; Alain-Jacques Valleron; Antoine Flahault; Fabrice Carrat
Journal:  Br J Gen Pract       Date:  2004-09       Impact factor: 5.386

Review 9.  [Transmission modes of hepatitis C virus].

Authors:  M Karmochkine; F Carrat; A J Valleron; G Raguin
Journal:  Presse Med       Date:  1998-05-16       Impact factor: 1.228

10.  [Nosocomial risk factors of hepatitis C infection. A multicenter study in a hospital-based population].

Authors:  S Maugat; P Astagneau; V Thibault; E Desruennes; N Baffoy; J-C Desenclos; G Brücker
Journal:  Rev Epidemiol Sante Publique       Date:  2003-06       Impact factor: 1.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.